vs
LCI INDUSTRIES（LCII）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
LCI INDUSTRIES的季度营收约是Revvity的1.2倍（$932.7M vs $772.1M），Revvity净利率更高（12.7% vs 2.0%，领先10.7%），LCI INDUSTRIES同比增速更快（16.1% vs 5.9%），Revvity自由现金流更多（$161.8M vs $64.3M），过去两年Revvity的营收复合增速更高（9.0% vs -1.8%）
拉奇核心工业有限公司前身为巴基斯坦帝国化学工业公司，是一家总部位于卡拉奇的巴基斯坦综合性企业集团，业务覆盖聚酯、医药、农用化学品、纯碱及兽药等多品类产品的研发生产，在巴基斯坦本土工业领域拥有重要市场地位。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
LCII vs RVTY — 直观对比
营收规模更大
LCII
是对方的1.2倍
$772.1M
营收增速更快
LCII
高出10.3%
5.9%
净利率更高
RVTY
高出10.7%
2.0%
自由现金流更多
RVTY
多$97.5M
$64.3M
两年增速更快
RVTY
近两年复合增速
-1.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $932.7M | $772.1M |
| 净利润 | $18.7M | $98.4M |
| 毛利率 | 22.1% | — |
| 营业利润率 | 3.8% | 14.5% |
| 净利率 | 2.0% | 12.7% |
| 营收同比 | 16.1% | 5.9% |
| 净利润同比 | 95.7% | 3.9% |
| 每股收益（稀释后） | $0.79 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LCIIRVTY
| Q4 25 | $932.7M | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $803.1M | $729.4M | ||
| Q3 24 | $915.5M | $684.0M | ||
| Q2 24 | $1.1B | $691.7M | ||
| Q1 24 | $968.0M | $649.9M |
净利润LCIIRVTY
| Q4 25 | $18.7M | $98.4M | ||
| Q3 25 | $62.5M | $46.7M | ||
| Q2 25 | $57.6M | $53.9M | ||
| Q1 25 | $49.4M | $42.2M | ||
| Q4 24 | $9.5M | $94.6M | ||
| Q3 24 | $35.6M | $94.4M | ||
| Q2 24 | $61.2M | $55.4M | ||
| Q1 24 | $36.5M | $26.0M |
毛利率LCIIRVTY
| Q4 25 | 22.1% | — | ||
| Q3 25 | 24.4% | 53.6% | ||
| Q2 25 | 24.4% | 54.5% | ||
| Q1 25 | 24.1% | 56.5% | ||
| Q4 24 | 21.1% | — | ||
| Q3 24 | 24.0% | 56.3% | ||
| Q2 24 | 25.3% | 55.7% | ||
| Q1 24 | 23.1% | 54.6% |
营业利润率LCIIRVTY
| Q4 25 | 3.8% | 14.5% | ||
| Q3 25 | 7.3% | 11.7% | ||
| Q2 25 | 7.9% | 12.6% | ||
| Q1 25 | 7.8% | 10.9% | ||
| Q4 24 | 2.0% | 16.3% | ||
| Q3 24 | 5.9% | 14.3% | ||
| Q2 24 | 8.6% | 12.4% | ||
| Q1 24 | 6.0% | 6.8% |
净利率LCIIRVTY
| Q4 25 | 2.0% | 12.7% | ||
| Q3 25 | 6.0% | 6.7% | ||
| Q2 25 | 5.2% | 7.5% | ||
| Q1 25 | 4.7% | 6.4% | ||
| Q4 24 | 1.2% | 13.0% | ||
| Q3 24 | 3.9% | 13.8% | ||
| Q2 24 | 5.8% | 8.0% | ||
| Q1 24 | 3.8% | 4.0% |
每股收益（稀释后）LCIIRVTY
| Q4 25 | $0.79 | $0.86 | ||
| Q3 25 | $2.55 | $0.40 | ||
| Q2 25 | $2.29 | $0.46 | ||
| Q1 25 | $1.94 | $0.35 | ||
| Q4 24 | $0.37 | $0.77 | ||
| Q3 24 | $1.39 | $0.77 | ||
| Q2 24 | $2.40 | $0.45 | ||
| Q1 24 | $1.44 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $222.6M | $919.9M |
| 总债务越低越好 | $945.2M | — |
| 股东权益账面价值 | $1.4B | $7.3B |
| 总资产 | $3.2B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.69× | — |
8季度趋势，按日历期对齐
现金及短期投资LCIIRVTY
| Q4 25 | $222.6M | $919.9M | ||
| Q3 25 | $199.7M | $931.4M | ||
| Q2 25 | $191.9M | $991.8M | ||
| Q1 25 | $231.2M | $1.1B | ||
| Q4 24 | $165.8M | $1.2B | ||
| Q3 24 | $161.2M | $1.2B | ||
| Q2 24 | $130.4M | $2.0B | ||
| Q1 24 | $22.6M | $1.7B |
总债务LCIIRVTY
| Q4 25 | $945.2M | — | ||
| Q3 25 | $947.8M | — | ||
| Q2 25 | $948.0M | — | ||
| Q1 25 | $938.3M | — | ||
| Q4 24 | $757.3M | — | ||
| Q3 24 | $822.5M | — | ||
| Q2 24 | $829.7M | — | ||
| Q1 24 | $855.3M | — |
股东权益LCIIRVTY
| Q4 25 | $1.4B | $7.3B | ||
| Q3 25 | $1.4B | $7.4B | ||
| Q2 25 | $1.4B | $7.6B | ||
| Q1 25 | $1.4B | $7.6B | ||
| Q4 24 | $1.4B | $7.7B | ||
| Q3 24 | $1.4B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B | ||
| Q1 24 | $1.4B | $7.8B |
总资产LCIIRVTY
| Q4 25 | $3.2B | $12.2B | ||
| Q3 25 | $3.2B | $12.1B | ||
| Q2 25 | $3.2B | $12.4B | ||
| Q1 25 | $3.1B | $12.4B | ||
| Q4 24 | $2.9B | $12.4B | ||
| Q3 24 | $3.0B | $12.8B | ||
| Q2 24 | $3.0B | $13.4B | ||
| Q1 24 | $3.0B | $13.4B |
负债/权益比LCIIRVTY
| Q4 25 | 0.69× | — | ||
| Q3 25 | 0.70× | — | ||
| Q2 25 | 0.68× | — | ||
| Q1 25 | 0.69× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.58× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.63× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $64.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.9% | 21.0% |
| 资本支出强度资本支出/营收 | 1.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 4.22× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $278.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流LCIIRVTY
| Q4 25 | $78.9M | $182.0M | ||
| Q3 25 | $97.2M | $138.5M | ||
| Q2 25 | $112.2M | $134.3M | ||
| Q1 25 | $42.7M | $128.2M | ||
| Q4 24 | $106.6M | $174.2M | ||
| Q3 24 | $78.4M | $147.9M | ||
| Q2 24 | $192.9M | $158.6M | ||
| Q1 24 | $-7.7M | $147.6M |
自由现金流LCIIRVTY
| Q4 25 | $64.3M | $161.8M | ||
| Q3 25 | $80.9M | $120.0M | ||
| Q2 25 | $99.5M | $115.5M | ||
| Q1 25 | $33.7M | $112.2M | ||
| Q4 24 | $95.7M | $149.8M | ||
| Q3 24 | $68.3M | $125.6M | ||
| Q2 24 | $180.2M | $136.6M | ||
| Q1 24 | $-16.3M | $129.7M |
自由现金流率LCIIRVTY
| Q4 25 | 6.9% | 21.0% | ||
| Q3 25 | 7.8% | 17.2% | ||
| Q2 25 | 9.0% | 16.0% | ||
| Q1 25 | 3.2% | 16.9% | ||
| Q4 24 | 11.9% | 20.5% | ||
| Q3 24 | 7.5% | 18.4% | ||
| Q2 24 | 17.1% | 19.7% | ||
| Q1 24 | -1.7% | 20.0% |
资本支出强度LCIIRVTY
| Q4 25 | 1.6% | 2.6% | ||
| Q3 25 | 1.6% | 2.6% | ||
| Q2 25 | 1.2% | 2.6% | ||
| Q1 25 | 0.9% | 2.4% | ||
| Q4 24 | 1.4% | 3.4% | ||
| Q3 24 | 1.1% | 3.3% | ||
| Q2 24 | 1.2% | 3.2% | ||
| Q1 24 | 0.9% | 2.7% |
现金转化率LCIIRVTY
| Q4 25 | 4.22× | 1.85× | ||
| Q3 25 | 1.55× | 2.97× | ||
| Q2 25 | 1.95× | 2.49× | ||
| Q1 25 | 0.86× | 3.03× | ||
| Q4 24 | 11.17× | 1.84× | ||
| Q3 24 | 2.20× | 1.57× | ||
| Q2 24 | 3.15× | 2.87× | ||
| Q1 24 | -0.21× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LCII
| Travel Trailer And Fifth Wheels | $378.4M | 41% |
| Chassis Chassis Partsand Slideout Mechanisms | $206.1M | 22% |
| Furnitureand Mattresses | $120.4M | 13% |
| Appliances | $69.9M | 7% |
| Other Products | $69.1M | 7% |
| Axlesand Suspension Solutions | $62.3M | 7% |
| Motorhomes | $34.2M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
